| Literature DB >> 26313722 |
Milton Sérgio Bohatch Júnior1, Paula Dayana Matkovski1, Frederico José Di Giovanni2, Romero Fenili1, Everton Luz Varella2, Anderson Dietrich2.
Abstract
OBJECTIVE: To determine the incidence of postoperative atrial fibrillation in patients undergoing on-pump and off-pump coronary artery bypass grafting.Entities:
Mesh:
Year: 2015 PMID: 26313722 PMCID: PMC4541778 DOI: 10.5935/1678-9741.20150040
Source DB: PubMed Journal: Rev Bras Cir Cardiovasc
Preoperative variables of patients undergoing on-pump and off-pump coronary artery bypass grafting.
| Technical Features | On-Pump (n=96) | Off-Pump (n=134) | |
|---|---|---|---|
| Age (years) (mean±SD) | (59.91±8.62) | (57.16±9.01) | 0.0213 |
| Age < 50 | 9 (9.4%) | 26 (19.4%) | 0.0360 |
| 50 ≤ i < 60 | 43 (44.8%) | 52 (38.8%) | 0.3632 |
| 60 ≤ i < 70 | 31 (32.3%) | 45 (33.6%) | 0.8374 |
| 70 ≤ i < 80 | 11 (11.5%) | 10 (7.5%) | 0.2995 |
| Age ≥ 80 | 2 (2.1%) | 1 (0.7%) | - |
| Female patients | 23 (24.2%) | 33 (24.6%) | 0.9424 |
| EuroSCORE | (3.37%±3.08%) | (3.13%±3%) | 0.5468 |
| Statins | 87 (90.6%) | 120 (89.6%) | 0.7891 |
| Beta-blocker | 87 (90.6%) | 111 (82.8%) | 0.0923 |
| Chronic coronary insufficiency | 45 (46.9%) | 73 (54.5%) | 0.2553 |
| Prior percutaneous angioplasty | 30 (31.25%) | 36 (26.87%) | 0.4685 |
| Diabetes Mellitus | 30 (31.25%) | 47 (35.07%) | 0.5444 |
| Hypertension | 73 (76.04%) | 107 (79.85%) | 0.4898 |
| Dyslipidemia | 64 (66.67%) | 86 (64.18%) | 0.6961 |
| Peripheral vascular disease | 4 (4.17%) | 9 (6.72%) | 0.4089 |
| Cerebrovascular disease | 6 (6.25%) | 11 (8.21%) | 0.5755 |
| Arteriopathy extracardiac | 61 (63.54%) | 73 (54.48%) | 0.1692 |
| Acute or chronic renal failure | 6 (6.25%) | 8 (5.97%) | 0.9302 |
| Chronic obstructive pulmonary disease | 8 (8.3%) | 13 (9.7%) | 0.7224 |
| Smokers | 23 (24%) | 30 (22.4%) | 0.2539 |
Intraoperative variables of patients undergoing on-pump and off-pump coronary artery bypass grafting.
| Technical Features | On-Pump (n=96) | Off-Pump (n=134) | |
|---|---|---|---|
| Number of grafts (Mean±SD) | (2.86±0.75) | (2.7±0.86) | 0.1357 |
| Blood products | 62 (64.58%) | 28 (20.9%) | 0.0000 |
| Packed red blood cells (units) | (2.35±0.89) | (1.71±0.73) | 0.0164 |
| Fresh frozen plasma (units) | (2.74±0.89) | (2.42±0.51) | 0.0957 |
| Platelets (units) | (8.6±3.66) | (7.33±2.52) | 0.5911 |
| Sympathomimetic drugs | 41 (42.71%) | 58 (43.28%) | 0.9308 |
| Dobutamine | 26 (27.08%) | 40 (30.08%) | 0.6218 |
| Noradrenaline | 11 (11.46%) | 17 (12.78%) | 0.7629 |
| Dopamine | 10 (10.42%) | 10 (7.46%) | 0.4330 |
| Vasodilators drugs | 22 (22.92%) | 29 (21.64%) | 0.8185 |
| Nitroglycerine | 7 (7.29%) | 12 (8.96%) | 0.6513 |
| Sodium nitroprusside | 18 (18.75%) | 18 (13.53%) | 0.2846 |
| Complications | 27 (28.13%) | 46 (34.33%) | 0.3189 |
| Increased bleeding | 5 (5.21%) | 6 (4.48%) | 0.7979 |
| Hemodynamic instability | 13 (13.54%) | 20 (14.93%) | 0.7678 |
| Arrhythmias | 9 (9.38%) | 23 (17.16%) | 0.0923 |
| Atrial fibrillation | 1 (1.04%) | 8 (6.02%) | 0.0560 |
| Pacemaker | 2 (2.08%) | 1 (0.75%) | 0.3781 |
| Intra-aortic balloon | - | 3 (2.24%) | 0.1400 |
| Acute myocardial infarction | - | 3 (2.24%) | 0.1400 |
| Mortality | - | - | - |
Postoperative variables of patients undergoing on-pump and off-pump coronary artery bypass grafting.
| Technical Features | On-Pump (n=96) | Off-Pump (n=134) | |
|---|---|---|---|
| Atrial Fibrillation | 19 (19.79%) | 18 (13.43%) | 0.1955 |
| Sympathomimetic drugs | 57 (59.38%) | 76 (56.72%) | 0.6872 |
| Dobutamine | 28 (29.17%) | 43 (32.09%) | 0.6361 |
| Noradrenaline | 43 (44.79%) | 48 (35.82%) | 0.1701 |
| Dopamine | 3 (3.13%) | 4 (2.99%) | 0.9514 |
| Adrenalin | 1 (1.04%) | - | 0.2364 |
| Vasodilators drugs | 43 (44.79%) | 63 (47.01%) | 0.7387 |
| Nitroglycerine | 28 (29.17%) | 53 (39.55%) | 0.1039 |
| Sodium nitroprusside | 25 (26.04%) | 25 (18.66%) | 0.1806 |
| Statins | 91 (94.79%) | 127 (94.78%) | 0.9958 |
| Beta-blocker | 85 (88.54%) | 118 (88.06%) | 0.9108 |
| Blood products | 27 (28.13%) | 25 (18.66%) | 0.0905 |
| Complications coronary care unit | |||
| Increased bleeding | 12 (12.5%) | 4 (2.99%) | 0.0052 |
| Reoperation | - | 1 (0.75%) | 0.3963 |
| Infectious complications | 8 (8.33%) | 8 (5.97%) | 0.4873 |
| Wound infection (chest) | 2 (2.1%) | 1 (0.7%) | 0.3781 |
| Bronchopneumonia | 5 (5.21%) | 7 (5.22%) | 0.9958 |
| Sepsis | 2 (2.08%) | 1 (0.75%) | 0.3781 |
| Delirium/altered levels of consciousness | 7 (7.29%) | 12 (8.96%) | 0.6513 |
| Ischemic stroke | 1 (1.04%) | 2 (1.49%) | 0.7663 |
| Acute renal failure | 4 (4.17%) | 2 (1.49%) | 0.2096 |
| Acute abdomen | 2 (2.08%) | - | 0.0933 |
| Pneumothorax/Pneumomediastinum | 2 (2.08%) | 4 (2.99%) | 0.6722 |
| Anemia | 26 (27.08%) | 22 (16.42%) | 0.0497 |
| Thrombocytopenia | 1 (1.04%) | 3 (2.24%) | 0.4934 |
| Hemodynamic instability | 10 (10.42%) | 7 (5.22%) | 0.1377 |
| Pericarditis | 1 (1.04%) | 4 (2.99%) | 0.3189 |
| Cardiopulmonary arrest | 4 (4.2%) | 4 (3%) | 0.6296 |
| Acute myocardial infarction | 1 (1.04%) | 2 (1.49%) | 0.7663 |
| Circulatory shock | 4 (4.17%) | 3 (2.24%) | 0.4013 |
| Intra-aortic balloon | - | 1 (0.75%) | 0.3963 |
| Time of Coronary Care Unit (days) | (3.21±2.23) | (3.22±2.7) | 0.9619 |
| Length of hospital stay (days) | (8.19±7.35) | (7.93±3.99) | 0.7513 |
| Mortality | 6 (6.3%) | 3 (2.2%) | 0.1218 |
Association of the variables with groups that have and have not developed postoperative atrial fibrillation in patients undergoing off-pump CABG.
| Variables | Developed atrial fibrillation (n=18) | Not developed atrial fibrillation (n=116) | |
|---|---|---|---|
| Preoperative | |||
| Female | 6 (33.3%) | 27 (23.3%) | 0.3568 |
| Age (> 70 years) | 4 (22.2%) | 5 (4.3%) | 0.0047 |
| Hypertension | 5 (27.8%) | 22 (19%) | 0.3858 |
| Diabetes Mellitus | 9 (50%) | 38 (32.8%) | 0.1538 |
| Chronic obstructive pulmonary disease | 1 (5.6%) | 12 (10.3%) | 0.5230 |
| Non-use of beta-blocker | 6 (33.3%) | 17 (14.7%) | 0.0505 |
| Non-use of statins | 2 (11.1%) | 12 (10.3%) | 0.9212 |
| Intraoperative | |||
| Blood products | 5 (27.8%) | 23 (19.8%) | 0.4402 |
| Arrhythmias | 4 (22.2%) | 19 (16.4%) | 0.5408 |
| Atrial fibrillation | 3 (16.7%) | 5 (4.3%) | 0.0410 |
| Ventricular fibrillation | 3 (16.7%) | 7 (6.1%) | 0.1135 |
| Ventricular extrasystole | 0 (0%) | 2 (1.7%) | 0.5729 |
| Sinus tachycardia | 0 (0%) | 2 (1.7%) | 0.5729 |
| Postoperative | |||
| Time of Coronary Care Unit (days) | (4.72±3.32) | (2.91±2.25) | 0.0374 |
| Length of hospital stay (days) | (9.89±4.09) | (7.62±3.91) | 0.0244 |
| Non-use of beta-blocker | 2 (11.1%) | 14 (12.1%) | 0.9072 |
| Non-use of statins | 2 (11.1%) | 5 (4.3%) | 0.2276 |
| Vasoactive drugs | 13 (72.2%) | 63 (54.3%) | 0.1536 |
| Infectious complications | 2 (11.1%) | 6 (5.2%) | 0.3225 |
| Mortality | 0 (0%) | 3 (2.6%) | 0.4902 |
Association of the variables with groups that have and have not developed postoperative atrial fibrillation in patients undergoing on-pump CABG.
| Variables | Developed atrial fibrillation (n=19) | Not developed atrial fibrillation (n=77) | |
|---|---|---|---|
| Preoperative | |||
| Female | 5 (26.3%) | 18 (23.7%) | 0.8107 |
| Age (> 70 years) | 6 (31.6%) | 5 (6.5%) | 0.0021 |
| Hypertension | 8 (42.1%) | 16 (20.8%) | 0.0545 |
| Diabetes Mellitus | 5 (26.3%) | 25 (32.5%) | 0.6044 |
| Chronic obstructive pulmonary disease | 2 (10.5%) | 6 (7.8%) | 0.6994 |
| Non-use of beta-blocker | 0 (0%) | 9 (11.7%) | 0.1175 |
| Non-use of statins | 1 (5.3%) | 8 (10.4%) | 0.4923 |
| Intraoperative | |||
| Aortic clamping time | (67.11±17.18) | (69.41±21.26) | 0.66299 |
| Cardiopulmonary bypass time | (100±23.69) | (104.41±26.6) | 0.51121 |
| Blood products | 12 (63.2%) | 50 (64.9%) | 0.8847 |
| Arrhythmias | 2 (10,5%) | 7 (9.1%) | 0.8476 |
| Atrial fibrillation | 1 (5.3%) | 0 (0%) | 0.0430 |
| Ventricular fibrillation | 1 (5.3%) | 3 (3.9%) | 0.7894 |
| Ventricular extrasystole | 0 (0%) | 1 (1.3%) | 0.6175 |
| Sinus tachycardia | 0 (0%) | 0 (0%) | - |
| Postoperative | |||
| Time of Coronary Care Unit (days) | (4.53±3.11) | (2.89±1.69) | 0.0652 |
| Length of hospital stay (days) | (10.26±11.26) | (7.68±6.01) | 0.3440 |
| Increased bleeding | 2 (10.5%) | 3 (3.9%) | 0.2441 |
| Non-use of beta-blocker | 5 (26.3%) | 6 (7.8%) | 0.0232 |
| Non-use of statins | 2 (10.5%) | 3 (3.9%) | 0.2441 |
| Vasoactive drugs | 14 (73.7%) | 43 (55.8%) | 0.1562 |
| Infectious complications | 4 (21.1%) | 4 (5.2%) | 0.0251 |
| Mortality | 4 (21.1%) | 2 (2.6%) | 0.0029 |
| AF | Atrial fibrillation |
| ARF | Acute renal failure |
| CABG | Coronary artery bypass grafting |
| CCU | Coronary care unit |
| COPD | Chronic obstructive pulmonary disease |
| CPB | Cardiopulmonary bypass |
| CRF | Chronic renal failure |
| DM | Diabetes mellitus |
| ECG | Ele ctroc ardi ograms |
| FURB | Regional University of Blumenau |
| ICU | Intensive care units |
| PTCA | Percutaneous transluminal angioplasty |
| PVD | Peripheral vascular disease |
| MSBJ | Analysis and/or interpretation of data; implementation of projects and/or experiments; manuscript writing or critical review of its content |
| PDM | Analysis and/or interpretation of data; implementation of projects and/or experiments; manuscript writing or critical review of its content |
| FJDG | Final approval of the manuscript; manuscript writing or critical review of its content |
| RF | Study design |
| ELV | Final approval of the manuscript |
| AD | Final approval of the manuscript; study design; manuscript writing or critical review of its content |